Introduction
Protein glycosylation is important for human brain development and function. Genetic deficiencies in this process lead to the congenital disorders of glycosylation (CDG) . The majority of the 470 known subtypes presents with intellectual disability (Wolfe and Krasnewich, 2013) . Patients with protein N-glycosylation defects can be identified through screening by serum transferrin isoelectric focusing. Defects in the assembly of the lipid-linked oligosaccharide and glycan transfer to nascent proteins in the endoplasmic reticulum typically lead to a multisystem disorder. The majority of patients in this group, CDG type I (CDG-I), can be diagnosed with currently 420 subtypes reported (Timal et al., 2012; Freeze, 2013) . Isolated intellectual disability is rare in CDG-I type glycosylation defects. Although some adult patients with PMM2-CDG have been described with intellectual disability and ataxia, without systemic abnormalities (Krasnewich et al., 2007) , and a few patients with DPAGT1-CDG, ALG2-CDG and ALG14-CDG were observed with global developmental delay with variable degree of myasthenia and subtle dysmorphism (Belaya et al., 2012; Cossins et al., 2013; Iqbal et al., 2013) , so far only two type I defects (MAGT1-CDG and TUSC3-CDG) have been reported with non-syndromic intellectual disability (Garshasbi et al., 2008; Molinari et al., 2008) . Elucidation of CDG-II defects, showing deficient glycan processing in the Golgi apparatus, is more complicated. The clinical spectrum is highly heterogeneous (Mohamed et al., 2011) and lacks clear clinical clues towards a diagnosis. For a limited number of Golgi defects, such as SLC35A1-CDG with intellectual disability and epilepsy (Mohamed et al., 2013) , glycan analysis of total serum proteins directly lead to a diagnosis. In contrast, non-syndromic autosomal recessive intellectual disability caused by ST3GAL3 mutations, a brain-specific glycosylation disorder, presents with normal serum transferrin glycosylation profiles . Intellectual disability can be caused by a large number of genetic disorders (Ellison et al., 2013) . Novel causative genes are regularly identified through massive next-generation sequencing efforts (Najmabadi et al., 2011; Veltman and Brunner, 2012 ). An example includes MAN1B1 deficiency, an autosomal-recessive intellectual disability (Rafiq et al., 2011) . The next challenge is to unravel the functional relevance of the plethora of new genetic variants by fast and highly specific diagnostic tests.
In this study, we apply a novel high resolution mass spectrometry method for direct glycoprofiling of intact plasma transferrin. This allowed the identification of 12 patients with MAN1B1-CDG, aged 1-35 years and presenting with an intellectual disability syndrome.
Materials and methods

Patient information and congenital disorder of glycosylation screening
Blood and fibroblasts of patients (clinical information in Table 2 ) were obtained for diagnostics of inborn errors of metabolism and used after informed consent from parents and treating physicians. Isoelectric focusing of serum transferrin for analysis of protein N-glycosylation defects and of serum apolipoprotein CIII for analysis of mucin type O-glycosylation defects were carried out as described before (Wopereis et al., 2007) . A transferrin polymorphism was excluded by neuraminidase digestion of the sample before transferrin isoelectric focusing.
Whole exome sequencing
Genomic DNA was extracted from fibroblast pellets of Patient 1 according to the manufacturer's protocol using a Qiagen Mini kit, and was checked for DNA degradation on agarose gels. Next generation sequencing and analysis was performed as described (Strá necký et al., 2013) . In brief, exome enrichment was performed using the SureSelect Human All Exon 50 Mb Kit (Agilent), covering $21 000 genes. The exome library was sequenced on a SOLiD 5500xl sequencer (Life Technologies). Colour space reads were iteratively mapped to the hg19 reference genome with the SOLiD LifeScope software version 2.1. Called variants and indels were annotated using an in-house annotation pipeline (Vissers et al., 2010) and common variants were filtered out based on a frequency of 40.5% in dbSNP and a frequency of 40.3% in our in-house database of 41300 exomes. Quality criteria were applied to filter out variants with less than five variant reads and 520% variation. Furthermore, synonymous variants, deep intronic, intergenic and untranslated region variants were excluded.
Sanger sequencing
Genomic DNA was extracted from fibroblast pellets or white blood cells from 12 patients and available family members. Primers (available on demand) were designed to amplify the different exons of the MAN1B1 gene (GenBank accession number NM_016219.4), including at least 50 bp of the flanking intronic regions. Standard PCR reactions were based on 1 ml DNA and 0.2 ml Platinum Õ Taq polymerase Mass spectrometry of total plasma protein N-glycans and affinity-enriched plasma proteins
Plasma N-glycan profiling of Patient 8.1 was performed by MALDI (Matrix-assisted laser desorption/ionization) linear ion trap mass spectrometry as described (Guillard et al., 2009) , using 10 ml of plasma. For high-resolution mass spectrometry of transferrin, a 10 ml plasma sample was incubated with anti-transferrin beads as described (Lacey et al., 2001) . The eluate was analysed on a microfluidic 6540 LC-chip-QTOF instrument (Agilent Technologies) using a C8 protein chip. Data analysis was performed using Agilent Mass Hunter Qualitative Analysis Software B.04.00. The Agilent BioConfirm Software was used to deconvolute the charge distribution raw data to reconstructed mass data.
Immunoglobulin G (IgG) and alpha1-antitrypsin (AAT) were affinityenriched from plasma using protein G and anti-AAT beads (CaptureSelect TM ; Life Technologies), respectively (Ruhaak et al., 2013) . N-glycans were enzymatically released, derivatized by methyl ester formation and lacton formation (Wheeler et al., 2009) , subsequently purified by hydrophilic interaction liquid chromatography-solid phase extraction (HILIC-SPE) and registered as sodium adducts by MALDI-TOF-MS (Selman et al., 2011) .
Results
Identification of MAN1B1 gene mutations
In our previous studies in patients with CDG-II, no clear clinical signs could be detected for further subgrouping of the patients.
In addition, biochemical analyses, including N-glycan profiling of total serum proteins, showed a general disturbance of the glycosylation process, not suggestive for a specific genetic defect (Mohamed et al., 2011) . To identify disease causing genes, DNA of several cases was submitted for whole exome sequencing.
After exome sequencing in Patient 1 (Table 2) , we ordered the genetic variants using a prioritization scheme as described earlier to identify the pathogenic mutation (Timal et al., 2012) . To this end, we excluded variants known in dbSNPv137 as well as variants from our in-house database, consisting of 41300 exomes from healthy individuals and patients with other rare diseases. This analysis reduced the number of candidate DNA variants to 238. Based on a recessive inheritance model, we identified 21 candidate genes (Supplementary Table 1 ), 19 with potential homozygous inheritance (determined by 480% variant reads), and two genes with compound heterozygous inheritance (determined by 420% variant reads). Of the nine variants, not previously annotated as single nucleotide polymorphisms (SNP), the c.1000C4T variant in MAN1B1 showed the highest level of conservation (PhyloP 5.938) with a sequencing depth of 102 reads and 100% variant reads. Moreover, MAN1B1, encoding mannosyl-oligosaccharide 1,2-alpha-mannosidase (EC 3.2.1.113) involved in the processing of N-glycans, was the only gene in the list that is correlated with protein N-glycosylation. Therefore, we considered this as the most likely disease-causing gene.
MAN1B1-congenital disorder of glycosylation shows specific glycosylation abnormalities
To identify more specific serum glycosylation markers for CDG-II diagnosis, we developed a high resolution mass spectrometry method to analyse the glycoprofile of an individual protein, by direct analysis of intact plasma transferrin. Ten microlitres of serum was used to immunopurify transferrin from patient samples, which could directly be analysed by nanochip-QTOF mass spectrometry using a C8 protein nanochip with a total analysis time of 52 h. In controls, a major peak is observed at 79 556 Da, corresponding with the molecular weight of the transferrin protein and two completely synthesized N-glycans (Fig. 1A) . In serum of Patient 1, a major glycosylated variant was found with a molecular mass of 79 224 Da with 450% abundance, corresponding with one hybrid type N-glycan and one normal glycan structure. In addition, a mass of 79 062 Da was observed, also corresponding with a hybrid type N-glycan (Fig. 1A) . The high-mass resolution allowed as to clearly discriminate these glycans from 79 260 Da indicating the loss of one sialic acid, which is present in similar amounts as in controls. The presence of both hybrid type N-glycans with one and two additional mannoses, respectively, is in agreement with deficient processing of protein linked glycans by the alpha-mannosidase MAN1B1.
The short sample preparation and analysis time of 52 h subsequently allowed us to screen our previous CDG-II cohort as well as newly included patients with severe and mild type II glycosylation abnormalities, 100 patients in total. In 11 additional patients, we could identify the presence of the same two hybrid type N-glycans at average mass of 79 224 Da and 79 062 Da, respectively (Fig. 1A and Supplementary Fig. 1 ). Inspection of the glycoprofile of total serum proteins in the previously analysed Patient 8.1 (Supplementary Fig. 2B ) showed the presence of a hybrid type N-glycan at mass to charge ratio (m/z) 2394 Da at an abundance of $10% relative to the main bi-antennary N-glycan at m/z 2796 Da. Other hybrid type N-glycans could be observed at m/z 2190, 2364, and 2568 as minor compounds. In total, the percentage of hybrid type glycans was 4.8% of the total plasma N-glycan pool (Supplementary Table 2 ). The presence of hybrid type Nglycans and high-mannose N-glycans was also detected in total serum glycoprofiles of a few other patients with unsolved CDG-II ( Supplementary Fig. 2C ) without the recognizable profile of intact transferrin. Additionally, increased fucosylation and the presence of truncated glycans lacking galactose and sialic acid were observed in those patients. Subsequently, we analysed N-glycans released from IgG ( Supplementary Fig. 3A ) and alpha1-antitrypsin (AAT, Supplementary Fig. 3B ), enriched from sera of five patients. Hybrid type N-glycans were clearly detectable for both proteins in all patients. The relative amount of hybrid type N-glycans compared with the total amount of N-glycans was 16.1% for IgG and 8% for AAT (Supplementary Table 2 ).
All 12 patients showed a recognizable profile in routine CDG screening by transferrin isoelectric focusing with an isolated increase of trisialotransferrin (28-38%, reference: 4.9-10.6%, Fig. 1B ). An identical profile is observed for a known polymorphism in the transferrin protein that can readily be recognized after treatment with neuraminidase (Fig. 1B ). An isolated increase of trisialotransferrin was observed more often in our cohort. However, the abundance was in general lower and no glycosylation abnormalities suggestive for MAN1B1-CDG could be observed by mass spectrometry of intact transferrin. Isoelectric focusing of APOC3 did not show abnormalities.
Sanger sequencing confirmed the presence of MAN1B1 mutations Sanger sequencing of the MAN1B1 gene was performed in DNA of all affected individuals with a characteristic glycosylation signature, and of available family members (Table 2 and Supplementary  Fig. 4 ). Five homozygous and four compound heterozygous mutations were identified. MAN1B1 belongs to the glycosyl hydrolase 47 family and consists of 699 amino acids with the catalytic pocket facing the organelle lumen as in a type II protein (Fig. 1C) . A crystal structure of the protein in complex with a disaccharide substrate (Karaveg et al., 2005) has indicated the specific amino acids that are required for enzymatic function and substrate binding. Missense mutations leading to amino acid substitutions (p.R334P, p.R334C, p.S409P, p.R597W, p.F659C, and p.E689K) were observed in highly conserved amino acid residues ( Supplementary Fig. 5 ). Arg334 is close to the active site and is suggested to influence the ionization state of the catalytic residue Glu330. Arg597 and Glu689 are involved in hydrogen bonding to the sugar substrate. Phe659 is also important for binding of the substrate by hydrophobic stacking. Four mutations leading to a premature stop codon were identified; p.W75X leads to a large truncation of the protein, whereas p.Q617X, p.W621X and p.E689X lead to a loss of the N-terminal 83, 79 and 11 amino acids, respectively. These include important amino acids for substrate and calcium binding such as Phe659, Glu663, Thr688, and Glu689. In Patient 6, apart from the p.S409P substitution, a heterozygous frameshift mutation was identified leading to a premature stop codon. Finally, in the two brothers of Family 8, a splice variant was identified at position À 2 of intron 4 at the paternal allele and a deletion of 13 bp in exon 4 at the maternal allele leading to a frameshift and a premature stop.
The identification of mutations in all patients with characteristic glycosylation abnormalities confirmed the efficiency of our novel mass spectrometric assay in the diagnosis of MAN1B1 deficiency.
Clinical presentation
The patient group (Table 2) showed a predominant neurological presentation with a wide range of mild to severe global developmental delay in all 12 patients. Intellectual disability was present in all patients 45 years. The degree of intellectual disability ranged from an IQ of 33 to 55, however, most patients were in the moderate disability range. All patients had speech delay. Muscle hypotonia was present in the majority of patients, leading to delayed motor skills. All patients showed delay in both gross and fine motor skills. Motor skills gradually improved in older patients, while abnormal speech remained a significant problem, even in adult age. Seizures were present in three patients. Brain MRI was performed in all patients except Patients 5.1 and 9. Mild abnormalities were reported for Patient 2 with a mildly delayed myelinization, and for Patient 7, showing mild cerebellar hypoplasia. Compared with previously reported cases only a few patients in our cohort had psychological/behavioural symptoms including aggressivity, autistic features or tics. In the current patient group, we found recognizable features like macrocephaly, truncal obesity and characteristic dysmorphism, including a flat oval face, low frontal hairline, curved eyebrows with lateral thinning, strabismus, prominent, bulbous nose tip and thin upper lip (Fig. 2) . Compared to patients with 'classic' CDG, only one-third of the patients had abnormal fat distribution or inverted nipples, and ataxia was also rare. None of the patients showed cutis laxa or wrinkled skin as observed in several CDG-II defects. No internal organ anomalies were noted. Laboratory abnormalities were found in a few patients, including mild coagulation abnormalities (slight elevation of partial thromboplastin and activated partial thromboplastin time in 1 of 9 and 1 of 10 patients, respectively) and mild liver function test elevations in 2 of 10 patients.
There was a striking variability in the phenotypic presentation of MAN1B1-deficient patients. In Family 4, Patient 4.1 shows features that are commonly present in other types of CDGs, including hypotonia, strabismus and inverted nipples, whereas the other sibling has a syndromal intellectual disability phenotype with macrocephaly, aggressivity and behavioural abnormalities. This intra-familial difference can be partially explained by the age difference. However, significant variability was reported in the two other sibling pairs (Patients 5.1 and 5.2, and Patients 8.1 and 8.2) as well, who had a more similar age. In Family 5, the older boy Table 1) . (B) Routine CDG screening by isoelectric focusing of serum transferrin showed an isolated increase of trisialotransferrin for all patients. The presence of a known polymorphism in the transferrin protein can complicate interpretation of the abnormal glycosylation. By treatment with neuraminidase ( + n), a single band is observed for MAN1B1-CDG, whereas a polymorphism is indicated by two bands after treatment with neuraminidase. (C) Schematic presentation of the MAN1B1 protein, indicating the cytosolic (Cyt), transmembrane (TM), and luminal parts. The amino acid substitutions identified in our patient cohort (Table 1) (Patient 5.1) was more severely affected than the younger girl (Patient 5.2) with more severe mental retardation and obesity. In the two adult patients of Family 8, the younger brother was more severely affected.
Discussion
In this paper, we describe a novel serum glycoprofiling method for functional diagnostic studies in MAN1B1 deficiency, an autosomal recessive intellectual disability syndrome. Defects in genes involved in the process of protein glycosylation contribute significantly to intellectual disability. The vast majority of the 470 known subtypes of CDG present with intellectual disability (Wolfe and Krasnewich, 2013) . In CDG-II, with defects in the processing steps in the Golgi apparatus, intellectual disability is present in the majority of subtypes as part of a multisystem presentation as well. B4GALT1-CDG is an exception without neurological symptoms . This is explained by the presence of a brain-specific isoform (B4GALT2) for this step in the glycosylation pathway. Especially the presence of fucose and sialic acid on protein glycans is important for proper functioning of glycoproteins in the brain, as exemplified by the presence of intellectual disability in SLC35C1-CDG (GDP-fucose transporter deficiency) and SLC35A1-and ST3GAL3-CDG (CMPsialic acid transporter and sialyltransferase deficiencies, respectively). MAN1B1 deficiency has been described as an intellectual disability syndrome, without significant associated findings, except facial dysmorphism (prominent nose and ear abnormalities and pointed chin in the three originally reported families; Rafiq et al., 2011) . Here, we report on 12 new patients with MAN1B1 deficiency and a neurological phenotype including global developmental delay, motor and speech delay, and hypotonia. As in the originally reported patients, our cohort shows associated dysmorphic features including truncal obesity and macrocephaly in $65% of the patients and abnormal fat distribution with inverted nipples in 5 of 12 patients. Variable facial dysmorphism was noted with thin lateral eyebrows, bulbous nose tip and thin upper lip as most common symptoms in about half of the patients. Mild liver involvement and coagulation factor deficiencies were found in a few patients. Very recently, a presentation of syndromic intellectual disability was also reported in a group of seven patients with MAN1B1-CDG (Rymen et al., 2013) . Based on the frequent presence of macrocephaly, subtle dysmorphic features and truncal obesity, MAN1B1-CDG should be indeed considered as a syndromic intellectual disability. As macrocephaly and obesity are also frequently present in healthy individuals, making a targeted, early diagnosis in the MAN1B1 cases could be difficult without screening for the suggestive glycosylation pattern abnormalities.
Interestingly, although the MAN1B1 enzyme is expressed in the whole body, the clinical features mainly involve the CNS. MAN1B1 deficiency prevents further removal of mannose residues during processing of protein linked N-glycans, which is required for the extension of the second antenna and subsequent synthesis of further branches on N-glycans. These branches typically contain polylactosamine extensions that can be decorated with specific sugar residues such as fucose that form essential glycan epitopes for cellular recognition. Our mass spectrometry experiments have shown that hybrid type N-glycans in MAN1B1-CDG are present on different proteins in variable amounts. Further glycoproteomic studies in model systems are required to identify the abnormally glycosylated brain proteins in MAN1B1-CDG that are particularly dependent on their glycans for normal function to identify a possible mechanism of disease. Another hint for disease pathology in MAN1B1-CDG originates from recent work showing altered Golgi morphology in patient fibroblasts, which could be related to the role of MAN1B1 in endoplasmic reticulum-associated degradation (Rymen et al., 2013) .
Analysis of intact transferrin more clearly highlights MAN1B1-specific abnormalities with accumulation of hybrid type N-glycans. In combination with the speed and robustness, this method is currently applied as a first step after CDG screening in our diagnostics of patients with unsolved CDG-II. With the emerging number of new patients with MAN1B1 mutations, MAN1B1-CDG seems to be a relatively common intellectual disability syndrome. Patients can be recognized based on the association of speech and learning disability with truncal obesity and a recognizable dysmorphic appearance. In such cases, direct application of our mass spectrometry method will quickly lead to a diagnosis. Several patients presented with intellectual disability without recognizable dysmorphic features or significant associated organ involvement, complicating a direct clinical diagnosis. Screening for CDG in patients with global developmental delay or intellectual disability with dysmorphic features is indicated even in the absence of associated liver function and coagulation abnormalities. The specific glycosylation pattern found in patients with the clinical trials of intellectual disability, macrocephaly and truncal obesity in MAN1B1-CDG is diagnostic. With the advent of nextgeneration sequencing, our method will prove highly valuable to confirm the functional relevance of genetic variants in MAN1B1 and to identify additional patients by analysis of CDG-II patient cohorts.
